© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
An international perspective pertaining to treatment advances in HER2-positive metastatic breast cancer and how to best apply data from ESMO 2021 into daily practice.
November 8th 2021
Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.
A global perspective regarding standards of care for treating HER2-positive metastatic breast cancer in earlier treatment settings.
November 15th 2021
Practice-changing data from the DESTINY-Breast03 trial evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer presented at ESMO 2021.
Subgroup analyses of the DESTINY-Breast03 study evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer.
November 22nd 2021
Recommendations for monitoring for and managing adverse events associated with newer therapies being sequenced into HER2+ metastatic breast cancer treatment algorithms.
Recommendations for managing patients with HER2+ metastatic breast cancer who develop interstitial lung disease, an adverse event of trastuzumab deruxtecan.
November 29th 2021
An overview of novel combination regimens being investigated for the treatment of HER2+ metastatic breast cancer.
Breast oncologists react to updated overall survival data, progression-free survival data, and quality-of-life data from the HER2CLIMB study of tucatinib for HER2+ metastatic breast cancer, as well as consider using the drug in combination with other novel therapies.
December 6th 2021
Recent advances in the characterization and treatment of patients with HER2-positive metastatic breast cancer and brain metastases.
Expectations as to where antibody-drug conjugates in the pipeline will fit into HER2-positive metastatic breast cancer treatment algorithms.
December 13th 2021
A global perspective pertaining to how to best sequence therapies used to treat HER2+ metastatic breast cancer based on treatment advances and data presented on at ESMO 2021.
A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.
Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.